drugset / Trial / NCT02148718
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.
Timeline
- Start
- 2014-06
- Primary completion
- 2016-08
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |